Stoke Therapeutics Inc Stock
Price
Target price
€11.10
€11.10
1.850%
0.2
1.850%
€21.00
09.05.24 / Tradegate
WKN: A2PLTL / Symbol: STOK / Name: Stoke Therapeutics / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Stoke Therapeutics Inc Stock
There is an upward development for Stoke Therapeutics Inc compared to yesterday, with an increase of €0.20 (1.850%).
With 15 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 21 € there is a hugely positive potential of 89.19% for Stoke Therapeutics Inc compared to the current price of 11.1 €.
So far the community has only identified positive things for Stoke Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | 1.850% | -0.893% | -6.723% | - | - | - | - |
| Immuron | -4.630% | -8.850% | -26.429% | -8.036% | 23.353% | -55.217% | - |
Comments
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat